Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat. Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake. Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
Faculty of Nursing. Catholic University of Murcia
Murcia, Spain
Percentage of total body weight loss
Change in body weight from baseline to the end of study period (3 months).
Time frame: 3 months
Plasma total cholesterol
Change in plasma total cholesterol levels from baseline to the end of study period (3 months).
Time frame: 3 months
Plasma low density level cholesterol (cLDL)
Change in plasma cLDL levels from baseline to the end of study period (3 months).
Time frame: 3 months
Plasma triglycerides
Change in plasma triglyceride levels from baseline to the end of study period (3 months).
Time frame: 3 months
Body mass index (BMI)
Change in BMI from baseline to the end of study period.
Time frame: 3 months
Body fat percentage
Change in body fat from baseline to the end of study period.
Time frame: 3 months
Waist circumference
Change in waist circumference from baseline to the end of study period.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.